|
Title
|
Published
|
Price
|
|
Nordic Pharma Development 2004
By: BioSeeker Group AB
BioSeeker Group's latest survey on drug development in the Nordic countries (Denmark, Finland, Norway and Sweden) gives you a comprehensive overview as well as detailed information on pharmaceutical R&D in the region. Our survey covers
|
more...
|
8/17/2004
|
$3,982.50
|
|
Basic Platform Report: Prostate Cancer
By: BioSeeker Group AB
Our Basic Platform Report: Prostate Cancer, provides a complete and systematic description of the current market of already established as well as new innovative therapies for the treatment of prostate cancer. In this informative report,
|
more...
|
8/15/2004
|
$3,894.00
|
|
Business Development and R&D Database: Prostate Cancer
By: BioSeeker Group AB
BioSeeker's Research Unit has released a unique CD-ROM database compiled to enable your independent and unbiased analysis of prostate cancer therapeutics progress and pitfalls as well as competition and business opportunities. The information in the
|
more...
|
8/15/2004
|
$3,984.00
|
|
Analytical Tool: Competitive Outlook on HCV
By: BioSeeker Group AB
BioSeeker Group's "Analytical Tool: Competitive Outlook on HCV", represents a powerful product combination of the independent and unbiased analytical report Competitive Outlook on HCV: What to Know & Expect in R&D and Business Development and
|
more...
|
7/7/2004
|
$1,125.00
|
|
Competitive Outlook on HCV: What to Know & Expect in R&D and Business Development
By: BioSeeker Group AB
The competitive business environment for the pharmaceutical market of chronic hepatitis C virus
(HCV) infection is fierce and changing. The entry of Hoffmann-La Roche into this $3 billion market,
previously dominated by Schering-Plough, has certainly
|
more...
|
6/22/2004
|
$749.00
|
|
HCV R&D and Business Development Database
By: BioSeeker Group AB
This unique CD-ROM database product is one of the most comprehensive and up to date information
sources on chronic hepatitis C virus R&D and business development. The database contains extensive
corporate, R&D, and business collaboration
|
more...
|
6/22/2004
|
$375.00
|
|
Analytical Tool: Competitive Outlook on HCV
By: BioSeeker Group AB
BioSeeker Group's "Analytical Tool: Competitive Outlook on HCV", represents a powerful product
combination of the independent and unbiased analytical report Competitive Outlook on HCV: What
to Know & Expect in R&D and Business Development and
|
more...
|
6/22/2004
|
$1,125.00
|
|
Ion Channel Drug Discovery - Therapeutic Opportunities & Technology Progress
By: BioSeeker Group AB
Increased knowledge of novel targets in combination with a strong progress in drug discovery technologies has strongly contributed to the fast development in ion channel drug discovery that we are witnessing today. This progress
|
more...
|
5/11/2004
|
$749.00
|
|
The Handbook on Alliances & Deals in Biotech Business
By: BioSeeker Group AB
"The only way to win in this business is to have alliances, both for small companies and large ones." (Executive manager of a large biotech company). The number of new alliances has increased ten-fold
|
more...
|
5/4/2004
|
$443.00
|
|
Nordic Biotech Industry Guide 2004
By: BioSeeker Group AB
The "Nordic Biotech Industry Guide 2004" is a unique CD product that contains a searchable database of more than 860 biotech companies (474 Swedish, 181 Finnish, 160 Danish and 50 Norwegian). BioSeeker has divided the
|
more...
|
2/17/2004
|
$1,348.65
|
|
Commercializing on Protein Kinase Inhibitors
By: BioSeeker Group AB
No analysis is better than the accuracy of the information that it is based upon. That is why BioSeeker Group has chosen to found "Commercializing on Protein Kinase Inhibitors" on the intellectual property of
|
more...
|
2/10/2004
|
$3,780.00
|
|
BSG Analytical Tool: Anticancer Integrin Antagonists
By: BioSeeker Group AB
Provide you with an analytical tool (database and report) for your in-depth analysis of this field. It is at the same time a map of the research and development, a history of the achievements
|
more...
|
2/9/2004
|
$2,632.50
|
|
BSG Analytical Tool: Anticancer VEGF/VEGFR Blockers
By: BioSeeker Group AB
Provide you with an analytical tool (database and report) for your in-depth analysis of this field. It is at the same time a map of the research and development, a history of the achievements
|
more...
|
2/8/2004
|
$5,332.50
|
|
BSG Analytical Tool: Anticancer Basal-Membrane Strategies
By: BioSeeker Group AB
Provides you with an analytical tool (database and report) for your in-depth analysis of this field. It is at the same time a map of the research and development, a history of the achievements
|
more...
|
2/8/2004
|
$2,632.50
|
|
BSG Analytical Tool: Antiangiogenesis & Vascular Targeting
By: BioSeeker Group AB
Despite important advances in understanding the molecular basis of cancer, few treatments have been devised to specifically target the known defects in tumor cells. Standard chemotherapy or radiation treatments are inherently non-selective and kill
|
more...
|
2/8/2004
|
$5,332.50
|
|
BSG Analytical R&D Tool - Analysis of Prostate Cancer R&D: The Complete Guide
By: BioSeeker Group AB
"Analysis of Prostate Cancer R&D - the Complete Guide" offers a unique tool for analysing the vast amount of strategic possibilities that have emerged in prostate cancer R&D. It is at the same time
|
more...
|
2/2/2004
|
$3,712.50
|
|
Finnish Biotech Industry Guide 2004
By: BioSeeker Group AB
The "Finnish Biotech Industry Guide 2004" is a unique CD product that contains a searchable database of more than 179 biotech companies. BioSeeker has divided the Finnish biotech industry into 16 different industry segments, such
|
more...
|
1/20/2004
|
$808.65
|
|
The Global Structure of Melanoma R&D
By: BioSeeker Group AB
Executive Summary
In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American
|
more...
|
11/10/2003
|
$2,700.00
|
|
The Melanoma R&D Database
By: BioSeeker Group AB
Decision-making requires a vast amount of structured information. Although paramount to establishing a representative description of a particular field, identifying and structuring information is a tedious task. When generating an information structure, it is essential
|
more...
|
11/10/2003
|
$3,982.50
|
|
The Future Battle Between Biopharmaceuticals and Biogenerics
By: BioSeeker Group AB
BioSeeker has analysed the opinions and arguments held by producers of biopharmaceuticals or generic-drug makers as well as regulatory authorities, in order to gain insight on how the near future guidelines will develop. We have
|
more...
|
10/30/2003
|
$3,375.00
|
|
Tumor Antigen & Cancer Vaccine Database
By: BioSeeker Group AB
BioSeeker Group has identified over 300 industry related R&D projects utilizing a tumor antigen strategy for anticancer immune stimulation. These projects have been grouped into four main categories - "pure" antigens or biological drugs, cell
|
more...
|
10/7/2003
|
$3,982.50
|
|
The Prostate Cancer R&D Database
By: BioSeeker Group AB
Decision-making requires a vast amount of structured information. Although paramount to establishing a representative description of a particular field, identifying and structuring information is a tedious task. When generating an information structure, it is
|
more...
|
9/18/2003
|
$3,982.50
|
|
National Swedish Biotech Address Registry
By: BioSeeker Group AB
The National Swedish Biotech Address Registry (NSBAR) is a rich source of updated addresses to key people within the Swedish biotech industry. This comprehensive address registry contains more than 2,400 positions in more than
|
more...
|
9/8/2003
|
$3,307.50
|
|
A Shift in Cancer Immunotherapy Strategies?
By: BioSeeker Group AB
"A Shift in Cancer Immunotherapy Strategies?" is the most extensive description and analysis of industry activities utilizing immunotherapeutic strategies for combating cancer. BioSeeker Group has analyzed more than 650 industry related cancer immunotherapy R&D
|
more...
Buy by the section | Search inside this report
|
7/25/2003
|
$3,712.50
|
|
New Lines of Attack in Cancer Anti-Angiogenesis
By: BioSeeker Group AB
Executive Summary:
Development of an adequate blood supply is one of the essential factors that dictate malignant growth and cancer development. An extensive number of companies seek to affect tumor growth by
|
more...
Buy by the section | Search inside this report
|
6/4/2003
|
$2,632.50
|
|
Title
|
Published
|
Price
|
(0 items)
